What the FDA labels say about taking them together
Insulin lispro and pramlintide
Insulin lispro's FDA label of June 4, 2025 names pramlintide in its drug interactions section; pramlintide's label does not name insulin lispro itself but warns about its class (insulin analogs). The insulin lispro label: “… disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. …”
Check it at the source: the insulin lispro FDA label on DailyMed (effective June 4, 2025, Sanofi-Aventis U.S. LLC); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the insulin lispro label say about pramlintide?
Insulin lispro label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs.
Source: FDA drug label (Insulin Lispro, BLA020563), Eli Lilly and Company, effective June 17, 2025 (SPL set 97d5e596-aae1-42c9-ae89-c3780959c467), via openFDA
Source: FDA drug label (ADMELOG), Sanofi-Aventis U.S. LLC, effective June 4, 2025 (SPL set 0691def8-4a7b-4de3-866f-a280989f47f1), via openFDA; the full label on DailyMed
What does the pramlintide label say about insulin lispro?
Pramlintide's label does not name insulin lispro itself; it warns about its class (insulin analogs):
Pramlintide label, boxed warningSEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
Pramlintide label, boxed warningAppropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin lispro | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $10.19 per mL 100 unit/mL kwikpen | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once